Evidence map›Paper›PMID 39236780›Full record

ArticleContemporary clinical trials2024

Methods to characterize lactate turnover in aging and Alzheimer's disease; The LEAN study.

Riley E Kemna, Paul J Kueck, Anneka E Blankenship, Casey S John, Chelsea N Johnson, Zachary D Green, Tyler Chamberlain, John P Thyfault, Jonathan D Mahnken, Benjamin F Miller and 1 more

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in Contemporary clinical trials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05207397 (Lactate for Energy and Neurocognition), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05207397 completednot on this map

Lactate for Energy and Neurocognition

TypeobservationalSponsorUniversity of Kansas Medical CenterRan2023 to 2024Enrolled24ConditionsHealthy Aging, Alzheimer DiseaseArmsLactate infusion
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Acute effects of lactate infusion on metabolism, AD biomarkers, and cognition: The LEAN study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Riley E KemnaUniversity of Kansas Alzheimer's Disease Research Center, United States of America; Department of Neurology, University of Kansas Medical Center, Kansas City, KS, United States of America.
Paul J KueckUniversity of Kansas Alzheimer's Disease Research Center, United States of America; Department of Neurology, University of Kansas Medical Center, Kansas City, KS, United States of America.
Anneka E BlankenshipUniversity of Kansas Alzheimer's Disease Research Center, United States of America; Department of Neurology, University of Kansas Medical Center, Kansas City, KS, United States of America.
Casey S JohnUniversity of Kansas Alzheimer's Disease Research Center, United States of America; Department of Neurology, University of Kansas Medical Center, Kansas City, KS, United States of America.
Chelsea N JohnsonUniversity of Kansas Alzheimer's Disease Research Center, United States of America; Department of Neurology, University of Kansas Medical Center, Kansas City, KS, United States of America; Cell Biology and Physiology, Universtiy of Kansas Medical Center, Kansas City, KS, United States of America.
Zachary D GreenUniversity of Kansas Alzheimer's Disease Research Center, United States of America; Department of Neurology, University of Kansas Medical Center, Kansas City, KS, United States of America.
Tyler ChamberlainO'Brien Pharmacy, Mission, KS, United States of America.
John P ThyfaultUniversity of Kansas Alzheimer's Disease Research Center, United States of America; Department of Neurology, University of Kansas Medical Center, Kansas City, KS, United States of America; Cell Biology and Physiology, Universtiy of Kansas Medical Center, Kansas City, KS, United States of America; Internal Medicine-Division of Endocrinology, Universtiy of Kansas Medical Center, Kansas City, KS, United States of America; Diabetes Institute, Universtiy of Kansas Medical Center, Kansas City, KS, United States of America.
Jonathan D MahnkenUniversity of Kansas Alzheimer's Disease Research Center, United States of America; Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, United States of America.
Benjamin F MillerAging and Metabolism Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States of America; Oklahoma City Veterance Association, Oklahoma City, OK, United States of America.
Jill K MorrisUniversity of Kansas Alzheimer's Disease Research Center, United States of America; Department of Neurology, University of Kansas Medical Center, Kansas City, KS, United States of America. Electronic address: jmorris2@kumc.edu.

Funding

RADx-UP: Improving the Response of Local Urban and Rural Communities to Disparities in Covid-19 TestingUL1TR002366 · NCATS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Mario Castro, JAMES STEVEN LEEDER · 2017 to 2026
$44.3M
University of Kansas Alzheimer's Disease Research Center (KU ADRC)P30AG072973 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Jaime Perales Puchalt · 2021 to 2026
$25.3M
University of Kansas Alzheimer's Disease Core CentersP30AG035982 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI BROOKS, WILLIAM M. · 2011 to 2020
$16.6M
longitudinal assessment of stress and stress-related concepts across a behavioral weight loss interventionP20GM144269 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Joseph E. Donnelly · 2022 to 2026
$14.9M
Acute exercise and the cerebral metabolic response in aging and Alzheimer's DiseaseR01AG062548 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI MORRIS, JILL KATHLEEN · 2020 to 2024
$2.4M
Feasibility of Improving Glycemia to Prevent Alzheimer's DiseaseR01AG081304 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Paige C Geiger, Jill Kathleen Morris · 2023 to 2026
$1.9M
Multidisciplinary Research Training Program in Alzheimer's Disease and Related DisordersT32AG078114 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Sandra A Billinger, Eric Dennis Vidoni · 2022 to 2026
$1.2M
Effects of metabolic phenotype on functional connectivity in aging and Alzheimer’s DiseaseF30AG076278 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI GREEN, ZACHARY DOUGLASS · 2022 to 2025
$180k
NCATS NIH HHS UL1 TR002366NIA NIH HHS F30 AG076278NIA NIH HHS P30 AG035982NIA NIH HHS P30 AG072973NIA NIH HHS R01 AG062548NIA NIH HHS R01 AG081304NIA NIH HHS T32 AG078114NIGMS NIH HHS P20 GM144269
6 · The paper itself

Abstract

backgroundThere is evidence that chronic exercise can benefit the brain, but the effects vary markedly between studies. One potential mechanism for exercise-related benefit is the increase in systemic lactate concentration that is well-characterized to occur during exercise. Lactate is known to cross the blood brain barrier and can be used readily as a fuel for neurons. This may be particularly important in Alzheimer's Disease, which is characterized by cerebral hypometabolism. However, little is known about how whole-body lactate metabolism differs between older adults and individuals with cognitive impairment. This information is critical when considering potential differences in responses to exercise in various cognitive diagnosis groups.

methodsHere we describe the use of a "lactate clamp" procedure to adjust blood lactate levels to approximate those achieved during exercise, but while at rest. This trial will compare lactate oxidation between cognitively healthy older adults and cognitively impaired participants. We will further evaluate the effect of acute lactate infusion on cognitive performance. DISCUSSION: The findings of the study described here, the Lactate for Energy and Neurocognition trial (clinicaltrials.gov # NCT05207397) will add to our understanding of systemic lactate mechanics in cognitively healthy older adults and individuals with Alzheimer's Disease. These findings will be applicable to ongoing exercise trials and to future studies aimed at modulating systemic bioenergetic function in aging and Alzheimer's Disease.

Indexed as

AgingAlzheimer DiseaseLactic AcidAgedClinical Trials as TopicCognitionCognitive DysfunctionExerciseFemaleHumansMaleLactic AcidAlzheimer's diseaseBrainExerciseLactateMetabolism

Identifiers

PMID39236780
PMCPMC11938302

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.